It took Barney Graham, Jason Mclellan and their collaborators just a weekend in January 2020 to design a novel vaccine they believed would be capable of protecting people against COVID-19. Their design formed the basis for the vaccines that Moderna, Pfizer and others would eventually use to inoculate millions of Americans a little more than a year later, a pace of development unprecedented in the annals of modern medicine.
By then, however, the two pioneering virologists were already thinking about future pandemics— and how they might get ahead of them.
Graham and McLellan are part of a corps of researchers hoping to take the technology they used on COVID-19 vaccines and apply them to an even more futuristic creation: an arsenal of off-the-shelf premade vaccines that could be easily modified to attack new pathogens as they arise—a kind of “pan” or “universal” coronavirus vaccine capable of protecting against many different strains of the virus at the same time.
Even as scientists race to develop booster shots and tweak existing vaccines to work against new variants to SARS2, they’re looking ahead to future pandemics caused by entirely new pathogens from the same coronavirus family, one of just 26 known to infect humans. But SARS-CoV-2 is the third novel, deadly coronavirus to cross over from animals to humans in the last 20 years, and many scientists warn more will inevitably follow. Even though a “universal” vaccine that can protect against any new coronavirus that nature throws at us probably won’t be available this year or next, development has become a high priority.
この記事は Newsweek の May 21 - 28, 2021 (Double Issue) 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は Newsweek の May 21 - 28, 2021 (Double Issue) 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
ARABIAIN MIGHT
SAUDI ARABIA'S INCREASING STRENGTH MEANS IT NOW HAS MUCH MORE CLOUT WITH ITS PARTNERS, INCLUDING THE U.S.
Bringing Trump's Trial to Life
Sketch artist Isabelle Brourman tells Newsweek what it was like covering the former president's court case
Iran Examines the Nuclear Option
Tehran's rhetoric could spark an arms race in the Middle East like never before
Climate Conviction at What Price?
Fifty years ago experts doubted Americans would pay to save the environment. Only some of their fears are still true
Most Loved Workplaces 2024
A THE WORLD'S MOST LOVED WORKPLACES ARE REMARKABLE FOR A variety of reasons.
Maya Hawke
MAYA HAWKE WEARS MANY HATS: ACTOR, WRITER, SINGER. BUT FOR Hawke, everything comes down to words.
Jacob Anderson
ANNE RICE'S NOVEL INTERVIEW WITH THE Vampire has a rabid fan base, intensely protective of the story and any adaptations of it.
VOTES OF NO CONFIDENCE
Why recent U.K. election results will ring alarm bells for Joe Biden
BIDEN'S BATTLEGROUND ELECTION
A small number of Democrats PROTESTING the president's support for Israel's war in Gaza could PREVENT him from winning a second term
'It's Time to Treat Addiction Like Cancer'
Both are serious illnesses but, unlike those struggling with substance use disorders, didn’t face shame and stigma when seeking help over my tumors